Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross-Sectional Descriptive Study as Part of the PharmLines Initiative.
CYP2C19
CYP2C9
CYP2D6
IADB.nl
Lifelines
drug-drug-interaction
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
11
2019
accepted:
20
04
2020
entrez:
28
5
2020
pubmed:
28
5
2020
medline:
28
5
2020
Statut:
epublish
Résumé
Drug-drug interaction (DDI) is one of the main contributors to adverse drug reactions and therefore, it is important to study its frequency in the population. We aimed to investigate frequency and concordance on CYP2D6, CYP2C19, and CYP2C9 (CYP2D6/2C19/2C9)-mediated potential DDIs at the Lifelines cohort and linked data from the pharmacy database IADB.nl. As part of the University of Groningen PharmLines Initiative, data were collected on CYP2D6/2C19/2C9-related substrate/inhibitors from entry questionnaires of Lifelines participants and linked information from the pharmacy database IADB.nl. CYP2D6/2C19/2C9 related co-prescriptions were divided based on the type of drugs i.e. chronically used medication (CM) or occasionally used medication (OM). This resulted in the combination of two chronically used drugs (CM-CM), chronically and occasionally used medication (CM-OM), and two occasionally used drugs (OM-OM). To measure the agreement level, cohen's kappa statistics and test characteristics were used. Results were stratified by time window, gender, and age. Among 80,837 medicine users in the Lifelines, about 1-2 per hundred participants were exposed to a CYP2D6/2C19/2C9-mediated potential DDI. Overall, the overlapping time window of three months produced the highest mean kappa values between the databases i.e. 0.545 (95% CI:0.544-0.545), 0.512 (95% CI:0.511-0.512), and 0.374 (95% CI:0.373-0.375), respectively. CM-CM had a better level of agreement (good) than CM-OM (fair to moderate) and OM-OM combination (poor to moderate). The influence of gender on concordance values was different for different CYPs. Among older persons, agreement levels were higher than for the younger population. CYP2D6/2C19/2C9-mediated potential DDIs were frequent and concordance of data varied by time window, type of combination, sex and age. Subsequent studies should rather use a combination of self-reported and pharmacy database information.
Sections du résumé
BACKGROUND
BACKGROUND
Drug-drug interaction (DDI) is one of the main contributors to adverse drug reactions and therefore, it is important to study its frequency in the population. We aimed to investigate frequency and concordance on CYP2D6, CYP2C19, and CYP2C9 (CYP2D6/2C19/2C9)-mediated potential DDIs at the Lifelines cohort and linked data from the pharmacy database IADB.nl.
METHODS
METHODS
As part of the University of Groningen PharmLines Initiative, data were collected on CYP2D6/2C19/2C9-related substrate/inhibitors from entry questionnaires of Lifelines participants and linked information from the pharmacy database IADB.nl. CYP2D6/2C19/2C9 related co-prescriptions were divided based on the type of drugs i.e. chronically used medication (CM) or occasionally used medication (OM). This resulted in the combination of two chronically used drugs (CM-CM), chronically and occasionally used medication (CM-OM), and two occasionally used drugs (OM-OM). To measure the agreement level, cohen's kappa statistics and test characteristics were used. Results were stratified by time window, gender, and age.
RESULTS
RESULTS
Among 80,837 medicine users in the Lifelines, about 1-2 per hundred participants were exposed to a CYP2D6/2C19/2C9-mediated potential DDI. Overall, the overlapping time window of three months produced the highest mean kappa values between the databases i.e. 0.545 (95% CI:0.544-0.545), 0.512 (95% CI:0.511-0.512), and 0.374 (95% CI:0.373-0.375), respectively. CM-CM had a better level of agreement (good) than CM-OM (fair to moderate) and OM-OM combination (poor to moderate). The influence of gender on concordance values was different for different CYPs. Among older persons, agreement levels were higher than for the younger population.
CONCLUSIONS
CONCLUSIONS
CYP2D6/2C19/2C9-mediated potential DDIs were frequent and concordance of data varied by time window, type of combination, sex and age. Subsequent studies should rather use a combination of self-reported and pharmacy database information.
Identifiants
pubmed: 32457621
doi: 10.3389/fphar.2020.00624
pmc: PMC7225338
doi:
Types de publication
Journal Article
Langues
eng
Pagination
624Informations de copyright
Copyright © 2020 Bahar, Bos, Borgsteede, Dotinga, Alingh, Wilffert and Hak.
Références
Br J Clin Pharmacol. 2018 Dec;84(12):2704-2715
pubmed: 30248178
J Clin Epidemiol. 2008 Sep;61(9):919-24
pubmed: 18468858
Ann Pharmacother. 2006 May;40(5):850-5
pubmed: 16622155
J Clin Epidemiol. 2005 Apr;58(4):323-37
pubmed: 15862718
Am J Epidemiol. 1995 Nov 15;142(10):1103-12
pubmed: 7485055
Int J Epidemiol. 2015 Aug;44(4):1172-80
pubmed: 25502107
BMC Med Res Methodol. 2011 May 18;11:72
pubmed: 21592352
Birth Defects Res A Clin Mol Teratol. 2012 Mar;94(3):153-61
pubmed: 22253196
Drug Saf. 2005;28(12):1131-9
pubmed: 16329715
Eur J Clin Pharmacol. 2006 Jun;62(6):463-72
pubmed: 16758263
Child Adolesc Psychiatr Clin N Am. 2000 Jan;9(1):43-76
pubmed: 10674190
Pharmacoepidemiol Drug Saf. 2016 Jan;25(1):82-9
pubmed: 26602064
Pharmacoepidemiol Drug Saf. 2017 Jul;26(7):752-765
pubmed: 28345306
J Clin Epidemiol. 2013 Nov;66(11):1308-16
pubmed: 23968693
J Am Geriatr Soc. 1991 Nov;39(11):1079-84
pubmed: 1753045
Anal Bioanal Chem. 2008 Nov;392(6):1093-108
pubmed: 18695978
Pharmacol Ther. 2013 Apr;138(1):103-41
pubmed: 23333322
JAMA. 2002 Jan 16;287(3):337-44
pubmed: 11790213
Res Social Adm Pharm. 2007 Mar;3(1):104-22
pubmed: 17350560
J Clin Epidemiol. 1997 Aug;50(8):975-80
pubmed: 9291884
J Clin Epidemiol. 1997 May;50(5):619-25
pubmed: 9180655
Drug Saf. 2007;30(10):911-8
pubmed: 17867728
PLoS One. 2015 Sep 02;10(9):e0137203
pubmed: 26333164
Drugs Aging. 2010 Sep 1;27(9):759-70
pubmed: 20809665
Pharm Weekbl Sci. 1991 Apr 26;13(2):91-6
pubmed: 1870949
Diabetologia. 2003 Mar;46(3):347-51
pubmed: 12687332
Cancer Lett. 2006 Mar 8;234(1):4-33
pubmed: 16504381
Psychiatr Prax. 1996 Sep;23(5):244-5
pubmed: 8992519
Br J Clin Pharmacol. 1998 Jun;45(6):591-5
pubmed: 9663815
J Oncol Pract. 2017 Mar;13(3):e217-e222
pubmed: 28095171
J Am Geriatr Soc. 1996 Aug;44(8):944-8
pubmed: 8708305
Toxicol Lett. 1998 Dec 28;102-103:149-54
pubmed: 10022247
Expert Opin Drug Saf. 2018 Jul;17(7):681-695
pubmed: 29952667
J Clin Epidemiol. 1989;42(12):1207-13
pubmed: 2585011
Int J Methods Psychiatr Res. 2010 Jun;19(2):88-96
pubmed: 20209650
J Clin Epidemiol. 2018 Feb;94:132-142
pubmed: 29097340
Pharmacoepidemiol Drug Saf. 2010 Jun;19(6):591-5
pubmed: 20535758
Pharmacoepidemiol Drug Saf. 2002 Jul-Aug;11(5):379-84
pubmed: 12271879
Pharmacogenomics. 2017 May;18(7):701-739
pubmed: 28480783
Clin Drug Investig. 2011;31(3):143-53
pubmed: 21142269
Lancet. 1993 Apr 10;341(8850):967-8
pubmed: 8096308
PLoS One. 2017 Mar 13;12(3):e0173530
pubmed: 28288183
Eur J Epidemiol. 2008;23(1):67-74
pubmed: 18075776
Ther Clin Risk Manag. 2015 Jul 15;11:1061-75
pubmed: 26203254
Eur J Clin Pharmacol. 2006 Sep;62(9):749-56
pubmed: 16896788
J Fam Pract. 2010 Jun;59(6):322-9
pubmed: 20544064
Br J Clin Pharmacol. 2018 Mar;84(3):542-552
pubmed: 29148077
Pharmacoepidemiol Drug Saf. 2018 Apr;27(4):413-421
pubmed: 29488294
Mayo Clin Proc. 2008 May;83(5):595-9
pubmed: 18452693
Pharmacoepidemiol Drug Saf. 2018 Jun;27(6):621-629
pubmed: 29575226
Eur J Clin Pharmacol. 2007 Nov;63(11):1069-74
pubmed: 17712552
Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):285-92
pubmed: 23763527
Curr Med Res Opin. 2018 Jun;34(6):1013-1019
pubmed: 29292657
Br J Clin Pharmacol. 2003 Jun;55(6):591-5
pubmed: 12814454
Clin Epidemiol. 2018 Aug 16;10:981-989
pubmed: 30147377
Epidemiology. 2001 Jul;12(4):461-6
pubmed: 11416783
BMJ. 1999 Oct 23;319(7217):1106-9
pubmed: 10531103
Expert Opin Drug Saf. 2012 Jan;11(1):83-94
pubmed: 22022824